vTv Therapeutics Q2 net loss $13.1M; Phase 3 T1D trial enrollment to complete Q3 2026

vTv Therapeutics Inc.

Net loss of $13.1M ($1.05 per share) vs $6.0M loss ($0.92) in Q2 2025; R&D spend rose to $8.8M from $4.1M.
Cash and equivalents $86.6M at June 30, 2026; company expects runway through CATT1 topline data readout.
Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes expected to complete enrollment in Q3 2026.
Phase 2a Hybrid CATT1 trial (hybrid closed-loop) to initiate before year-end 2026; KOL event planned Q4 2026.
Six-month revenue of $36.8M (vs $0 in prior year) from a milestone; net income of $11.1M for H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.